Investors have told us that out of all the therapeutic assets they review, 50% are uninvestable or very difficult to work with as a result of mismanagement. At LSN, we often stress the importance of a company's management team, and we support our clients in positioning a team to effectively showcase their experience and expertise. The team matters precisely because there's a lot of ways a good therapeutic asset can be damaged by poor management decisions. This article will bring together some advice we've heard in conversation with experienced therapeutic investors and at the RESI Conference about what can go wrong at an early stage of therapeutic development that will damage a company's future chances of finding an investor or a strategic partner.

Establishing a strong IP position is the issue most likely to cause difficulties for an inexperienced entrepreneur. If you're attempting to commercialize a scientific discovery made at a research institution, it's vital to ensure that your IP position is solid...

   READ MORE   

The medical device industry has long been plagued by a lack of early stage venture capital, with investors in the space often citing uncertain regulatory issuers, reimbursement and adoption as reasons for not heavily allocating into the sector. As such many medical device companies find themselves unable to secure funds from traditional venture capital firms. More and more large and established companies interested in the medical device space however are looking further upstream for innovative companies to collaborate with and add into their product lines. LSN's research team has spoken with over 60 of these companies across 17 countries, who have established corporate venture funds or allocating directly off of their balance sheet, to identify the types and stages of technologies that they are currently looking for...

   READ MORE  

An increasing number of innovative entrepreneurs are finding capital, development partners, and distribution channels outside of their geographic region. Who is investing outside of their geographic regions? What are their motivations? What are the benefits and risks when working with cross-border investors? Six experts from prominent VC funds and corporations gathered at the Redefining Early Stage Investments (RESI) conference in Boston on September 16 to address these questions.

Moderated by Lisa Rhoads, Managing Director, Easton Capital, the panel featured:

   READ MORE